BioCentury | Sep 10, 2018
Distillery Therapeutics

Cancer

...Inc. unit market Tarceva to treat NSCLC, brain and pancreatic cancer. Marina Biotech Inc. has CEQ508...
BioCentury | May 23, 2018
Distillery Therapeutics

Cancer

...Pharma Inc. market Xtandi, an androgen receptor antagonist, for prostate cancer. Marina Biotech Inc. has CEQ508...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

...to treat psoriasis and Phase I testing to treat HCV-induced cirrhosis. Marina Biotech Inc. has CEQ508...
BioCentury | Apr 11, 2016
Company News

Marina Biotech, Microlin Bio deal

...based on Microlin’s close of $1.50 before the deal was announced. The deal includes Marina’s CEQ508...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...in preclinical testing. Marina Biotech Inc. 's CEQ508...
...CTNNB1 ) mRNA to the intestine. CEQ508...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

...inhibitor PRI-724 in Phase I/II testing to treat CML and other cancers. Marina Biotech Inc.'s CEQ508...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...Chugai Pharmaceutical Co. Ltd. market Herceptin to treat breast and gastric cancers. Marina Biotech Inc.'s CEQ508...
BioCentury | Aug 27, 2012
Company News

Marina Biotech cancer news

...including the Phase Ib/IIa START-FAP trial evaluating CEQ508 in patients with familial adenomatous polyposis (FAP). CEQ508...
BioCentury | Jun 11, 2012
Company News

Marina Biotech cancer news

...of its employees and ceased most day-to-day operations, including the Phase Ib/IIa START-FAP trial evaluating CEQ508...
...in the near-term, Marina said it may need to further reduce or cease operations completely. CEQ508...
BioCentury | Apr 30, 2012
Company News

Marina Biotech, Cambridge Biolabs LLC deal

...evaluating Marina's CEQ508 in patients with familial adenomatous polyposis (FAP) are expected early next year. CEQ508...
Items per page:
1 - 10 of 22